Literature DB >> 11455983

Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx.

V Ribrag1, M Ell Hajj, F Janot, T Girinsky, C Domenge, G Schwaab, P Fenaux, J Bosq.   

Abstract

Nasal NK/T cell is a rare form of usually localized non-Hodgkin's lymphoma (NHL) which generally carries a poor prognosis when treated with conventional NHL chemotherapy protocols. We reviewed 20 consecutive localized stage I/II nasal NK/T cell lymphomas treated at our institution over a 29 year period. Median age was 44 (range 23-71). Front-line therapy was generally radiotherapy alone (35-70 Gy) before 1980 and combination chemotherapy after 1980. Six patients were treated with first-line radiotherapy and they achieved complete remission (CR). Two subsequently received combination chemotherapy. Five of those patients remained in complete remission, after 97+ to 277+ months. Twelve patients were treated with first-line chemotherapy including CHOP or CHOP-like regimen in seven cases, and COP in five cases. Only three of them achieved CR, five had partial response and four had progressive disease. Five of the seven patients treated with CHOP did not achieve complete remission. The nine patients who failed to achieve CR with chemotherapy subsequently received salvage radiotherapy but only two of them obtained CR. Finally, two patients were treated with alternated chemotherapy and radiotherapy and achieved CR, which persisted after 14+ and 26+ months. Median survival was not reached in patients who received front-line radiotherapy, and was 35 months in patients who received front-line chemotherapy. These findings confirm that chemotherapy gives a low complete remission rate in localized nasal NK/T cell lymphoma. By contrast, first-line radiotherapy seems to give favorable results, whereas its results are poorer when administered after resistance to chemotherapy. Whether the use of chemotherapy after radiotherapy, or alternated chemotherapy-radiotherapy regimens give better clinical results than radiotherapy alone will have to be evaluated prospectively in this type of NHL.

Entities:  

Mesh:

Year:  2001        PMID: 11455983     DOI: 10.1038/sj.leu.2402148

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.

Authors:  Hui-Hui Ma; Li-Ting Qian; Hai-Feng Pan; Lin Yang; Hong-Yan Zhang; Zhi-Hua Wang; Jun Ma; Yu-Fei Zhao; Jin Gao; Ai-Dong Wu
Journal:  Med Oncol       Date:  2009-08-15       Impact factor: 3.064

2.  Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy.

Authors:  Agustin Avilés; Natividad Neri; Raúl Fernández; Angel Calva; Judith Huerta-Guzmán; M Jesús Nambo
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 3.  Treatment of localized extranodal NK/T cell lymphoma, nasal type.

Authors:  Seok Jin Kim; Won Seog Kim
Journal:  Int J Hematol       Date:  2010-11-18       Impact factor: 2.490

4.  Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma.

Authors:  Yao Zhang; Yizhen Liu; Zuguang Xia; Jia Jin; Kai Xue; Jiachen Wang; Hui Sun; Fangfang Lv; Xiaojian Liu; Junning Cao; Xiaonan Hong; Ye Guo; Xuejun Ma; Qunling Zhang
Journal:  Ann Transl Med       Date:  2021-07

Review 5.  Extranodal NK/T-cell lymphoma nasal type: efficacy of pegaspargase. Report of two patients from the United Sates and review of literature.

Authors:  Vincent Edgar Reyes; Tahseen Al-Saleem; Valentin G Robu; Mitchell R Smith
Journal:  Leuk Res       Date:  2009-09-27       Impact factor: 3.156

6.  Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.

Authors:  Liang Wang; Zhong-jun Xia; Hui-qiang Huang; Yue Lu; Yu-jing Zhang
Journal:  Int J Hematol       Date:  2012-09-16       Impact factor: 2.490

7.  Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.

Authors:  Li Yang; Hong Liu; Xiao-hong Xu; Xin-feng Wang; Hong-ming Huang; Wen-yu Shi; Sheng-hua Jiang
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

8.  A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.

Authors:  Abeer N Abouyabis; Pareen J Shenoy; Rajni Sinha; Christopher R Flowers; Mary Jo Lechowicz
Journal:  ISRN Hematol       Date:  2011-06-16

9.  The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma.

Authors:  Koh-ichi Sakata; Masanori Someya; Mutsuko Omatsu; Hiroko Asanuma; Tadashi Hasegawa; Shingo Ichimiya; Masato Hareyama; Tetsuo Himi
Journal:  BMC Cancer       Date:  2007-12-19       Impact factor: 4.430

10.  Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma.

Authors:  Yoshiomi Hatayama; Masahiko Aoki; Hideo Kawaguchi; Yuichiro Narita; Katsumi Hirose; Mariko Sato; Yoshihiro Takai
Journal:  Mol Clin Oncol       Date:  2013-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.